Sökning: onr:"swepub:oai:gup.ub.gu.se/115696" >
Evaluation and regi...
Evaluation and registration of adverse events in clinical drug trials in migraine.
-
Tfelt-Hansen, P (författare)
-
Bjarnason, N H (författare)
-
- Dahlöf, Carl, 1947 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för klinisk neurovetenskap och rehabilitering,Institute of Neuroscience and Physiology, Department of Clinical Neuroscience and Rehabilitation
-
visa fler...
-
Derry, S (författare)
-
Loder, E (författare)
-
Massiou, H (författare)
-
visa färre...
-
(creator_code:org_t)
- 2008-07-01
- 2008
- Engelska.
-
Ingår i: Cephalalgia : an international journal of headache. - : SAGE Publications. - 1468-2982. ; 28:7, s. 683-8
- Relaterad länk:
-
https://journals.sag...
-
visa fler...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Tolerability of a drug should be regarded as important as its efficacy. In all four phases of drug development evaluation of adverse events is important. Recommendations for assessment of adverse events in acute and prophylactic clinical drug trials in migraine are given. Tolerability may be indirectly assessed using measures of general well-being and eight such tools are presented. Finally, recommendations for reporting of adverse events are given.
Nyckelord
- Adverse Drug Reaction Reporting Systems
- Analgesics
- adverse effects
- therapeutic use
- Cross-Over Studies
- Dose-Response Relationship
- Drug
- Double-Blind Method
- Drug Administration Schedule
- Humans
- Migraine Disorders
- drug therapy
- Randomized Controlled Trials as Topic
- Registries
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas